The situation of the K Therapy being in short supply soon emerged.
The production process of the K Factor is complex, with limited capacity. Medical systems in many European and American countries began discussing the priority usage standards, while insurance companies urgently evaluated coverage plans. Rumors in the black market suggest that the price of a single K Factor has skyrocketed to $500,000.
And all of this spotlighted the theorist—Yang Ping and his leadership at the Sanbo Research Institute.
The first wave of visitors was a joint delegation from the Harvard-MIT Broad Institute, consisting of six world-class cancer genomics and systems biology experts. They came with dozens of sharp questions, planning a three-day academic exchange.
Yang Ping did not receive them in the meeting room but directly brought them into the laboratory.
